MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-11-2026
Cronos Group Depreciation & Amortization 2011-2026 | CRON
Annual Depreciation & Amortization Cronos Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.2 M | 9.34 M | 8.11 M | 13.1 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.2 M | 8.11 M | 11.2 M |
Quarterly Depreciation & Amortization Cronos Group
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.73 M | 10.6 M | 7.04 M | 2.84 M | 6.81 M | 3.24 M | 1.73 M | 6.93 M | 4.78 M | 2.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10.6 M | 1.73 M | 5.01 M |
Depreciation & Amortization of other stocks in the Drug manufacturers industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Endo International plc
ENDP
|
306 M | - | - | $ 28.9 M |  Irlanda |
 |
AcelRx Pharmaceuticals
ACRX
|
311 K | - | 7.5 % | $ 6.35 M |  USA |
 |
DURECT Corporation
DRRX
|
84 K | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
1.48 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
6.4 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
102 K | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
8.75 M | - | - | $ 142 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
4.15 M | $ 5.77 | -1.7 % | $ 85.7 M | USA |
 |
Athenex
ATNX
|
4.47 M | - | -23.39 % | $ 1.76 M | USA |
 |
Harrow Health
HROW
|
1.32 M | $ 34.17 | 3.55 % | $ 1.26 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
2.68 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
489 M | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
646 K | - | -39.89 % | $ 27.7 M | USA |
 |
Bausch Health Companies
BHC
|
1.21 B | $ 5.4 | -1.28 % | $ 2 B |  Canada |
 |
Organogenesis Holdings
ORGO
|
15.3 M | $ 2.66 | - | $ 337 M | USA |
 |
Pacira BioSciences
PCRX
|
78.8 M | $ 24.36 | 4.33 % | $ 1.13 B | USA |
 |
Canopy Growth Corporation
CGC
|
21.5 M | $ 1.05 | 0.96 % | $ 113 M | Canada |
 |
Solid Biosciences
SLDB
|
1.64 M | $ 6.88 | 3.93 % | $ 602 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
138 K | $ 1.06 | -3.64 % | $ 1.32 M | USA |
 |
Jupiter Wellness
JUPW
|
654 K | - | - | $ 33.6 M | USA |
 |
Tilray
TLRY
|
35.7 M | $ 5.45 | 3.02 % | $ 3.37 B | Canada |
 |
Lannett Company
LCI
|
34.3 M | - | 1.15 % | $ 7.11 M | USA |
 |
Evolus
EOLS
|
7.51 M | $ 6.25 | 2.63 % | $ 403 M | USA |
 |
Emergent BioSolutions
EBS
|
95.8 M | $ 9.13 | 8.05 % | $ 488 M | USA |
 |
Veru
VERU
|
152 K | $ 2.31 | -1.7 % | $ 33.8 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
3.04 M | - | - | $ 193 M | Canada |
 |
Assertio Holdings
ASRT
|
30 M | $ 23.46 | 0.09 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
4.72 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
1.16 M | - | - | $ 1.42 B | USA |
 |
cbdMD
YCBD
|
361 K | $ 0.76 | -0.12 % | $ 3.06 M | USA |
 |
PetIQ
PETQ
|
44.5 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
1.26 K | $ 7.17 | 1.85 % | $ 283 M | USA |
 |
Recro Pharma
REPH
|
8.22 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
402 K | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
580 K | $ 0.68 | -6.88 % | $ 34 M | USA |
 |
PLx Pharma
PLXP
|
116 K | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
2.8 B | $ 16.26 | -2.34 % | $ 18.9 B | USA |
 |
Zomedica Corp.
ZOM
|
2.06 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
219 K | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
2.19 M | $ 0.76 | -4.74 % | $ 27.3 M | USA |
 |
Tricida
TCDA
|
442 K | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
1.5 M | $ 0.78 | 2.67 % | $ 3.35 M |  China |
 |
TherapeuticsMD
TXMD
|
384 K | $ 2.11 | -0.47 % | $ 24.4 M | USA |